Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
Titel:
Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
Auteur:
Maroun, J.A. Belanger, K. Seymour, L. Matthews, S. Roach, J. Dionne, J. Soulieres, D. Stewart, D. Goel, R. Charpentier, D. Goss, G. Tomiak, E. Yau, J. Jimeno, J. Chiritescu, G.